levothyroxine sodium accord 88 mikrogrami tabletes
accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 88 μg
levothyroxine sodium accord 112 mikrogrami tabletes
accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 112 μg
levothyroxine sodium accord 137 mikrogrami tabletes
accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 137 μg
levothyroxine sodium accord 150 mikrogrami tabletes
accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 150 μg
levothyroxine sodium accord 175 mikrogrami tabletes
accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 175 μg
levothyroxine sodium accord 200 mikrogrami tabletes
accord healthcare b.v., netherlands - levotiroksīna nātrija sāls - tablete - 200 μg
meropenem accord 1 g pulveris injekciju/infūziju šķīduma pagatavošanai
accord healthcare b.v., netherlands - meropenēms - pulveris injekciju/infūziju šķīduma pagatavošanai - 1 g
allopurinol accord 100 mg tabletes
accord healthcare b.v., netherlands - allopurinols - tablete - 100 mg
allopurinol accord 300 mg tabletes
accord healthcare b.v., netherlands - allopurinols - tablete - 300 mg
rivaroxaban accord
accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombotiskie līdzekļi - venozās trombembolijas (vte) profilakse pieaugušiem pacientiem, kuriem tiek veikta gēnu vai ceļa locītavas locītavas operācija. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 haemodynamically nestabila pe pacientiem). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 un 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Ārstēšana ar dziļo vēnu tromboze (dvt) un plaušu embolija (pe), un novērst atkārtotu dvt un pe pieaugušajiem. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.